Does IBD Increase Risk for Oral Cancer?

Patients with inflammatory bowel diseases (IBD) have an increased risk of oral cancers—especially tongue cancer—researchers report in the March issue of Clinical Gastroenterology and Hepatology. Women are at higher risk than men. Oral cancers develop in the mucosal surfaces of the lips, floor of mouth, tongue, buccal mucosa, lower and

Read more

Should Patients with Crohn’s Disease Continue Receiving Immunomodulators When Starting Anti-TNF Therapy?

Continued use of immunomodulator therapy in patients with Crohn’s disease receiving anti-tumor necrosis factor (TNF) therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission, researchers show. The meta-analysis of randomized controlled trials is published in the December issue of Clinical Gastroenterology and Hepatology. There is debate

Read more
  • What Loci Determine Susceptibility to IBD in African Americans?

What Loci Determine Susceptibility to IBD in African Americans?

Although many of the same genetic variants determine susceptibility to inflammatory bowel diseases (IBD) in Caucasians and African Americans, researchers report the identification of variants and loci not previously associated with IBD in African American populations. Analyses of these could provide insight into the pathogenesis of IBD, researchers state in

Read more
  • This is Your Brain on Anti-TNF Therapy

This is Your Brain on Anti-TNF Therapy

Anti-tumor necrosis factor (anti-TNF) agents rapidly reduce pain perception in brains of patients with Crohn’s disease, researchers show in the October issue of Gastroenterology. This observation could explain how clinical disease activity is often reduced long before signs of mucosal healing. Patients with Crohn’s disease treated with anti-TNF agents often report reductions in abdominal pain

Read more
  • Special Issue: Genetics, Genetic Testing, and Biomarkers of Digestive Diseases

Special Issue: Genetics, Genetic Testing, and Biomarkers of Digestive Diseases

A special issue of Gastroenterology features 14 articles discussing the genetic factors that contribute to a range of gastrointestinal (GI),  hepatobiliary, and pancreatic diseases, and how this information can be used in diagnosis and treatment of patients. An introduction to the special issue explains the value of associating diseases with specific genetic variants, which can help

Read more
  • Anemia—a Real Problem for Patients With IBD

Anemia—a Real Problem for Patients With IBD

Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease (IBD), researchers report in the October issue of Clinical Gastroenterology and Hepatology. Persistent or recurrent anemia could be used as a marker of severe disease and to identify patients who require aggressive management. Anemia is a well-recognized but underestimated problem

Read more
  • Can Curcumin Treat Mild-to-Moderate Ulcerative Colitis?

Can Curcumin Treat Mild-to-Moderate Ulcerative Colitis?

Addition of curcumin to mesalamine therapy increases its ability to induce clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis (UC), researchers show in the August issue of Clinical Gastroenterology and Hepatology. Patients with mild-to-moderate UC are usually treated with oral and/or topical mesalamine. Those who do not

Read more
  • A Temperature-sensitive Gel For Topical Administration of Colitis Drugs

A Temperature-sensitive Gel For Topical Administration of Colitis Drugs

Researchers describe a system for topical delivery of drugs to patients with ulcerative colitis (UC). A polymer that holds and then releases UC drugs such as budesonide and mesalamine is liquid at room temperature, but turns into a viscous gel upon reaching body temperature, they report in the July issue of Gastroenterology. Systemic therapies for inflammatory

Read more
  • Is FMT Ready for IBD?

Is FMT Ready for IBD?

Despite promising findings from 2 studies of fecal microbiota transplantation (FMT) in patients with ulcerative colitis, the technology should remain in clinical trials and is not ready for routine practice in patients with inflammatory bowel diseases (IBD), write Ari M. Grinspan and Colleen R. Kelly in an editorial. The success of FMT

Read more
  • New Approaches to IBS and IBD, But Concerns About PPIs, Highlighted at DDW

New Approaches to IBS and IBD, But Concerns About PPIs, Highlighted at DDW

A new test to identify diarrhea-predominant irritable bowel syndrome (D-IBS) and a new class of drugs to treat ulcerative colitis were presented at Digestive Disease Week (DDW) in Washington DC, May 15–19. Researchers also warned that many residents of nursing homes are being inappropriately given proton pump inhibitors (PPIs). Mark Pimentel

Read more